Inclusion Criteria:

          -  Male or female subjects aged greater than or equal to (>=) 18 years

          -  With Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1 at
             trial entry

          -  At least 1 measurable tumor lesion

          -  With histologically confirmed metastatic or recurrent (Stage IV) non-small cell lung
             cancer (NSCLC)

          -  With availability of a recently-obtained, formalin-fixed, paraffin-embedded (FFPE)
             tissue sample containing tumor (biopsy from a non-irradiated area preferably within 6
             months) or a minimum number of 10 (preferably 25) unstained tumor slides cut within 1
             week, and suitable for PD-L1 expression assessment

          -  Subjects must not have received any treatment for systemic lung cancer, and have an
             estimated life expectancy of more than 12 weeks

          -  Other protocol defined criteria could apply

        Exclusion Criteria:

          -  Subjects whose disease harbors a EGFR mutation, or anaplastic lymphoma kinase (ALK)
             rearrangement are not eligible.

          -  Other exclusion criteria include prior therapy with any antibody or drug targeting T
             cell coregulatory proteins, concurrent anticancer treatment, or immunosuppressive
             agents

          -  Known severe hypersensitivity reactions to monoclonal antibodies (Grade >= 3 NCI CTCAE
             v 4.03), history of anaphylaxis, or uncontrolled asthma (that is, 3 or more features
             of partially controlled asthma), and persisting toxicity related to prior therapy of
             Grade > 1 NCI-CTCAE v 4.03.

          -  Subjects with brain metastases are excluded, except those meeting the following
             criteria: brain metastases that have been treated locally and are clinically stable
             for at least 2 weeks prior to randomization, subjects must be either off steroids or
             on a stable or decreasing dose of <= 10 mg daily prednisone (or equivalent), and do
             not have ongoing neurological symptoms that are related to the brain localization of
             the disease.

          -  Other protocol defined criteria could apply